Coherus Acquires Bevacizumab Rights From Innovent

Deal Also Includes Option To Sell Innovent’s Rituximab Biosimilar

 
• By David Wallace
  
Coherus
Coherus has acquired rights to an Avastin biosimilar from Innovent • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business